Evidence map›Paper›PMID 33355478›Full record

Trial reportCanadian journal of psychiatry. Revue canadienne de psychiatrie2021

Adjunctive

Alyna Turner, Andrea Baker, Olivia M Dean, Adam J Walker, Seetal Dodd, Susan M Cotton, James G Scott, Bianca E Kavanagh, Melanie M Ashton, Ellie Brown and 2 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Alyna Turner2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.ORCID 0000-0001-7389-2546
Andrea Baker90131Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia.
Olivia M Dean2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
Adam J Walker2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
Seetal Dodd2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
Susan M CottonCentre for Youth Mental Health, The University of Melbourne, Parkville, Australia.
James G Scott90131Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia.
Bianca E Kavanagh2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.ORCID 0000-0002-1656-2775
Melanie M Ashton2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.ORCID 0000-0001-6832-4157
Ellie Brown2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
John J McGrath90131Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia.ORCID 0000-0002-4792-6068
Michael Berk2104Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.ORCID 0000-0002-5554-6946
Barwon Health · AUThe Royal Melbourne Hospital · AUPark Centre for Mental Health · AUQIMR Berghofer Medical Research Institute · AUThe University of Melbourne · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives

methodsPeople diagnosed with schizophrenia or schizoaffective disorder (

resultsBaseline assessments were conducted on 148 people (mangosteen = 74, placebo = 74); data analyses were conducted on 136 (92%) participants with postbaseline data. The treatment group had significantly higher symptom severity compared to placebo, and both groups significantly improved on all symptom, functioning, and quality of life measures over time. No between-group differences were found for the rate of change between baseline and 24 or 28 weeks.

conclusionDespite promising preclinical and clinical work, our results do not support mangosteen pericarp extract as an adjunctive treatment for schizophrenia or schizoaffective disorder.

Indexed as

Garcinia mangostanaPsychotic DisordersSchizophreniaDouble-Blind MethodHumansQuality of LifeVictoriaclinical trialGarcinia mangostana Linninflammationmangosteenmental disordersoxidative stresspsychiatryschizoaffective disorderschizophreniatreatment

Identifiers

PMID33355478
PMCPMC8172349
OpenAlexW3113870451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.